Leerink Partners Reiterates Market Perform Rating on Myriad Genetics, Inc. (MYGN)

Market Context

Myriad Genetics, Inc. operates in the Healthcare sector. The stock currently trades at $6.29 with a market capitalization of $680.9M. The stock has declined 26.4% over the past 52 weeks.

Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Myriad Genetics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Myriad Genetics, Inc.

Among the 10 most recent ratings: 1 Buy, 8 Hold, 1 Sell.

Date	Firm	Rating	Price Target
Nov 05, 2026	TD Cowen	Hold	N/A
Nov 05, 2026	Leerink Partners	Market Perform	N/A
Oct 13, 2026	TD Cowen	Hold	N/A
Oct 02, 2026	Craig-Hallum	Buy	N/A
Sep 09, 2026	UBS	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View MYGN Stock Page